Several studies suggest that the histocompatibility complex (HLA) class I region harbours genes modulating multiple sclerosis (MS) susceptibility independently from the effect of class II alleles. A candidate gene in this region is MOG, encoding the myelin oligodendrocyte glycoprotein. A significant association with the missense variation V142L (rs2857766) was previously reported in a small sample of 50 Italian MS patients. We confirmed this result in two independent Italian sample sets consisting of 878 MS patients and 890 matched controls (P ¼ 6.6 Â 10 À4 ) and 246 trio families (P ¼ 1.5 Â 10 À3
Introduction
Multiple sclerosis (MS) is a demyelinating autoimmune disease of the central nervous system 1 caused by an interplay of environmental and genetic factors. [2] [3] [4] The only genetic factor that has been clearly demonstrated by linkage and association studies maps in the human major histocompatibility complex (HLA) region. In particular, the class II allele HLA-DRB1*1501 (DR15) is positively associated in all tested Caucasoid populations. [5] [6] [7] The only exception is represented by Sardinia where the frequency of DR15 is low both in patients and controls, while MS is principally associated with DR4 and DR3. 8 Although a weaker positive association with DR4 9-12 and DR3 13 has been reported also in other populations, this was not detected in a large case-control study in continental Italy. 6 Negative associations have also been reported. 6, 7 More recently, several studies suggested that genes located in the HLA class I region modulate susceptibility to MS independently of class II. Fogdell-Hahn et al.
14 and Harbo et al. 15 found a significantly increased frequency of the class I HLA-A*03 allele in northern Europe MS patients. The A*03 allele is part of the extended HLA haplotype (hp) characterized by DR15. However, the effect of this association was additive to the risk conferred by DR15 and not a consequence of linkage disequilibrium (LD) between the two alleles. In addition Fogdell-Hahn et al. 14 found a protective effect of HLA-A*02. This was confirmed in a larger Swedish panel. 16 A protective effect independent of HLA class II was recently detected for HLA-Cw*05 in a large UK and US cohort of simplex families and sporadic cases. 17 Rubio et al. 18, 19 reported in Tasmanian patients with European ancestry a significant association with D6S265 and MOGCA microsatellites mapping in the HLA class I region 100 kb centromeric and 500 kb telomeric to HLA-A, respectively. In addition they found that having class I and II susceptibility variants on the same hp provides an additive effect on MS risk. In the Sardinian population the D6S1683 microsatellite, located about 980 kb telomeric to HLA-A, was significantly associated 20 with MS independently of class II. Altogether these data point to the presence of at least one MS risk gene, either additive to or independent of class II, in a region of about 1 MB in the HLA class I region.
A very interesting candidate gene mapping in this region is MOG, encoding the myelin oligodendrocyte glycoprotein, a quantitatively minor component of myelin which is specific of the central nervous system and is located exclusively on the surface of myelin sheaths and olygodendrocytes. 21 MOG is a potential target antigen of the central nervous system, known to induce an autoreactive T-cell response and pathogenic demyelinating anti-MOG antibodies in MS patients and in EAE (experimental autoimmune encephalomyelitis) mice, the animal model of MS. [22] [23] [24] So far, association studies of MOG markers with MS susceptibility yielded conflicting results. No association was found in 169 French MS patients 25 with three MOG dinucleotide repeats, whereas a significant association was reported for one of these markers (MOGCA) in the above mentioned Tasmanian patients 18, 19 and by Barcellos et al. 26 Single nucleotide polymorphisms (SNPs) located in the MOG 5 0 flanking and coding region were not associated with MS susceptibility in 100 German paediatric patients, 27 82 French adult patients 28 and in 397 Sardinian trio families. 29 Conversely, in the continental Italian population a significant association with the missense variation V142L in the MOG transmembrane region was reported in a small sample of 50 MS patients. 30 Possible explanations of the inconsistency among the different studies might be population differences and/or the small sample sizes.
The aim of the present study was to confirm the Italian finding in a larger independent sample. To this purpose an association study with the V142L SNP was performed by both a case-control and an intrafamilial association approach. We confirmed the result previously reported in the continental Italian population. Consequent steps were to examine whether this association was independent of known MS susceptibility factors in the HLA region and if other sequence variations in the MOG gene and in the class I region were more significantly associated with MS.
Results

Association with MOG-V142L polymorphism
The MS association with the V142L MOG missense variation was tested in two independent Italian sample sets consisting of 878 MS patients and 890 controls (sample set 1) and 246 simplex families including the MS patient and both parents (sample set 2). Significantly different case and control allele frequencies were observed in both sample sets (P ¼ 6.6 Â 10 À4 , P ¼ 1.5 Â 10
À3
) and in the combined sample (P ¼ 6.7 Â 10 À6 ). In particular, the (Table 3 ). All individuals were categorized according to the DRB1*15 and L142 status (grouped as positive/negative for each of them). The OR conferred by L142 (0.70) remained similar after accounting for DRB1*15 carrier status (0.72). Moreover, the MS risk conferred by DRB1*15 (OR ¼ 2.81) did not change when adjusted for the presence of L142 (OR ¼ 2.77). The interaction between the two markers was also tested in the model: no evidence of interaction was found (P ¼ 0.40). These data demonstrate that the involvement of MOG L142 in MS susceptibility was not secondary to the well-known major effect of DRB*15. Moreover, the effect of these two MS-associated alleles was not reciprocally modified.
Although the majority of the DRB1 association with MS is attributable to DRB1*15, other DRB1 alleles are also involved in MS susceptibility. 6, 7, 17 We therefore considered the relationship between the V142L association and all DRB1 alleles in a random subset of 540 MS cases and 558 controls fully typed for DRB1. A weak LD was detected between MOG V142L and DRB1 (global D' ¼ 0.19, Cramer's V ¼ 0.17 in the patients; D' ¼ 0.17, Cramer's V ¼ 0.17 in the controls). V142L was still significantly associated in this panel after conditioning on the DRB1 locus by the COCAPHASE program (unconditioned P ¼ 0.0031; conditioned P ¼ 0.035). Moreover, both in the total panel and in DRB1*15-negative individuals, the OR conferred by L142 remained similar after accounting for each DRB1 allele separately by logistic regression modelling (data not shown).
Having proved that the V142L association is independent of HLA-DR, we then tested its relationship with other polymorphisms in the MOG gene and in the HLA class I region. This analysis was mainly performed in the trio families in order to be able to directly deduce haplotypic combinations from family segregation.
Test of association with other MOG sequence variations
The involvement of MOG in MS susceptibility was further tested by analysing the association with 11 SNPs, of which 4 in the 5 0 flanking, 3 in the coding and 4 in the 3 0 untranslated regions of the gene ( Figure 1b ). All the selected SNPs were detected directly in MS patients. SNPs in MOG-5 0 flanking and coding regions were selected from the literature and were detected by extensive sequencing of these regions in Italian 30 and German 27 patients. Since no sequencing scan was available for the 3 0 -UTR in MS patients, we screened MOG 3 0 -UTR (1195 bp) in 25 patients by DHPLC and identified 4 variations. Three of these had been previously detected in normal individuals and are included in the SNP database (http://www.ncbi.nlm.nih.gov/ SNP/). The association was first tested by TDT in the trio families already analysed for position 142. Complete genotyping results for all the tested SNPs were obtained for 199 families. In this random subset of families L142 was still preferentially non-transmitted (T:NT ¼ 31:63; P ¼ 0.001). Conversely, none of the other SNPs showed a significant transmission distortion. To increase the power of our analysis we further tested the association of MOG SNPs by a case-control analysis in 290 controls and 343 patients. Combining the two sets (trios and cases/ controls) we were able to compare allele frequencies of 1084 case and 978 control chromosomes. Considering a range from 0.05 to 0.20 of the minor allele frequency of the tested SNPs, this sample size has an 80% power to detect a risk factor conferring an OR ranging from 1.35 to 1.6 at an a level of 0.05 (for comparison, the V142 allele in this panel conferred an OR ¼ 1.5). Thus, this study had sufficient power to detect a risk factor with an ORBV142L for the majority of tested SNPs with the exception of the rare -1077T/C, -910T/C and Indel L22 variations. None of the tested MOG SNPs, besides MOG V142L, was significantly associated with MS (Table 4) . The same result was obtained when including only Linkage disequilibria between V142L and the tested MOG SNPs are shown in Table 5 . V142L showed a modestly significant LD only with S5S and V145I.
TDT results on the hps including all the analysed SNPs are shown in Table 6 . Ten hps, accounting for 89% of the total, had a frequency higher than 0.01. The remaining hps showed a frequency p0.01 both in the patients and in controls. L142 was mainly included in one hp (hp no. 3) Sum of the patient chromosomes from the 343 cases of the case/control study and the transmitted chromosomes in 199 simplex families. SNPsÀ1077T/C and Indel L22 were analysed only in the families. e Sum of the control chromosomes from the 290 controls of the case/control study and the non-transmitted chromosomes in 199 simplex families. SNPsÀ1077T/C and Indel L22 were analysed only in the families. 
Involvement of
With the only exception of position 142, this hp shared the same markers with hp no. 1 which, as opposed to hp no. 3, was significantly over-transmitted (P ¼ 0.002). When V142L was removed from the analysis, the transmission of this hp combination was no longer distorted. One further rare hp (no. 7) showed a transmission distortion (P ¼ 0.03) either including or excluding position 142 in the analysis. This association was no longer significant when considering only DRB1*15-negative families (Table 6 ). Conversely, hp no. 3 carrying L142 remained significantly under-transmitted also in DRB1*15-negative families (P ¼ 0.007).
Besides the above 11 SNPs, we tested in the same MS families the association of an MOG intragenic microsatellite, MOGTAAA, located in the 3 0 -UTR (Figure 1) . None of the microsatellite alleles or of their hp combinations with the tested SNPs was significantly associated.
In conclusion, none of the tested variations in the MOG gene showed an association with MSXV142L. Thus the association with V142L was not secondary to any other tested MOG variation.
Test of association with other markers of the HLA class I region To test whether the association observed for V142L extended outside the MOG gene, we analysed the MS association of six microsatellites (five in the class I region and tumour-necrosis factor a (TNFa); Figure 1a) in the 199 families already tested for all MOG SNPs. None of the microsatellite alleles showed a significant transmission distortion. Among those previously reported to be significantly associated, 15, [18] [19] [20] 26 a non-significant trend was observed only for the MOGCA allele 5 (T:NT 72:52, P ¼ 0.073).
L142 showed a significant LD with the microsatellite alleles MOGCA-6 and D6S265-5 ( Table 5 ). The transmission of the three allele hps (L142, MOGCA-6, D6S265-5) was distorted (T:NT 12:20) but not significantly (P ¼ 0.16), while a significantly lower transmission (T:NT 13:28, P ¼ 0.019) was seen for the two allele hps (L142, D6S265-5). When considering only L142-negative chromosomes, no transmission distortion was observed either for D6S265-5 (T:NT 18:17) or for MOGCA-6 (T:NT 2:3).
Discussion
Our results strongly support the presence of an additional MS risk-modulating element in the HLA class I region, independent of DRB1 alleles, and point to MOG V142L as the possible involved factor in the Italian population.
The association of MOG V142L with MS susceptibility was detected by two independent, population-and family-based, association studies, thus confirming a previously reported result in a small sample of 50 Italian MS patients. 30 Notably V142L was the only SNP in the MOG gene significantly associated to MS, in accordance with previous negative results 28, 33, 34 obtained for MOG markers not including V142L. Besides the continental Italian population, the association of V142L was previously tested in one study performed in German paediatric MS patients and in a recent study in the Table 5 Linkage disequilibria calculated in the simplex families Only the microsatellite alleles with a significant LD with V142L are included. *Po0.05. **Po0.01. ***Po0.001; LDs involving V142L are indicated in bold.
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Sardinian population. In both studies it was not significantly associated with MS. 27, 29 This discrepant result may be related to the different population, to the different age of onset of the disease or to the sample size.
The MOG142 association with MS was not modified when conditioning the analysis on HLA-DRB1 alleles. Thus the protective effect of L142 is independent of HLA-DRB1.
While it is possible that MOG142 is only a marker in LD with a causative sequence variation mapping in an unexplored sequence inside or outside the MOG gene, the possibility of a primary involvement of MOG142 is, however, indicated by the following circumstantial evidence:
(1) a V at position 142 is conserved among all tested mammalian species (mouse, rat, cow, macaca, orangutan), suggesting that it has a non-dispensable functional role; (2) V142L is a conservative substitution located in the first MOG transmembrane domain. There are several instances of diseases in which V/L variations in transmembrane domains (for example in proteins encoded by CFTR, ABC7, PSEN1, TSHR, ACHR, VKORC1) were shown to be causative mutations (references [35] [36] [37] [38] [39] and www.genet.sickkids.on.ca/cftr).
What could be the role in MS susceptibility of a conservative V-L substitution in an MOG transmembrane domain? One possible mechanism could be related to the role of MOG as an autoantigen. [22] [23] [24] 40, 41 Immunization of experimental animals with MOG peptides induces EAE. 22 Interestingly, there is a high similarity between MOGinduced animal models and biopsies from MS patients, both showing large demyelinating lesions and axonal loss. 42, 43 MOG has an extracellular part including aa 1-122 with an immunnoglobulin-like domain, a transmembrane part from aa 123 to 152 and an intracellular and a second transmembrane part 21 comprising aa 123-218. Up to now, T-cell responses against the extracellular part of MOG have been mainly looked at. However more recent data show that the intracellular part of MOG is much more immunogenic than the extracellular part. 44 In particular, there is a dominant MOG epitope recognized by CD4 þ T cells within the intracellular part of MOG comprising amino acids immediately flanking the 142 residue. The reported experiments were performed only with the more frequent V142 sequence. As an attractive hypothesis, the L residue could confer protection for MS by decreasing the immunogenicity of this epitope. Notably, analysis by computer programs (http:// www.immuneepitope.org, http://www.syfpeithi.de/) showed that the presence of either V or L at position 142 changes the affinity score for class I and class II HLA molecules.
A second proposed mechanism refers to the possible influence of transmembrane variations on signal transmission. In fact, mutations in transmembrane sequences of different plasma membrane receptors alter the signalling cascade by affecting the correct repartition into the glycosphingolipid-cholesterol membrane microdomains 45, 46 ('lipid rafts'). According to current models, upon ligand or antibody cross-linking, different plasma membrane receptors undergo enhanced repartitioning into lipid rafts as an obligatory first step towards participation in early signal-transduction events. Lipid rafts provide a specialized environment for novel molecular interactions that can activate signal-transduction pathways. Recent data demonstrated that the signalling cascade activated by antibody cross-linking of MOG is dependent on MOG repartition into lipid rafts. 47 It is tempting to speculate that the V142L substitution could influence MOG repartition into lipid rafts and hence signal transduction.
Finally, missense variations modifying exonic splicing enhancer (ESE) or silencer sites have been reported as causative mutations of genetic diseases. 48 However, the involvement of MOG exon 3 missense SNP in this mechanism seems unlikely since (1) the known alternatively spliced isoforms of human MOG do not involve In conclusion, our data confirm the presence of an MS risk factor, independent of HLA-DR, in the HLA class I region and propose that it might be located in the MOG gene. The relationship between MOG L142 and the other recently identified HLA class I protective markers 14, 16, 17 (HLA-A2 and -Cw5) remains to be tested. In addition, its possible pathogenetic role should be clarified by functional analysis.
Materials and methods
Subjects
Two independent Italian sample sets were analysed, namely sample set 1 consisting of 878 MS patients (female:male ratio 2:1) and 890 controls (medical students, university and hospital staff, blood donors, female:male ratio 1:1), and sample set 2 consisting of 246 simplex families including the MS patients (female: male ratio 1.75:1) and their parents. Enrolment followed their informed consent. Patients were diagnosed according to McDonald et al. 49 All patients had a relapsingremitting onset and included patients with relapsingremitting and secondary progressive disease course defined according to Lublin and Reingold. 50 Patients with a primary progressive disease course were excluded as well as patients with Sardinian ancestors to avoid the introduction of confounding sources of heterogeneity.
Search for sequence variations in the MOG 3 0 -UTR region The MOG 3 0 -UTR region (1195 bp) was amplified from genomic DNA of 25 MS patients as 4 overlapping PCR fragments including the whole 3 0 -UTR with the exception of the most distal 113 bp containing the MOGTAAA microsatellite. PCR primers were designed on the genomic DNA Genbank sequence AL050328.24 (version GI: 7530094).
Search for sequence variations was performed by DHPLC (denaturing high-performance liquid chromatography) on an automated HPLC instrument (Wave, Transgenomic Santa Clara, CA, USA) as previously reported. 51 The temperature required for successful resolution of heteroduplex molecules was determined using a specific program (website http://insertion. stanford.edu/melt.html). Samples were analysed at the predicted temperatures (RTm) and at RTm þ 2 1C as recommended by the software authors. 52 Primers used for amplification and DHPLC conditions are available upon request. The PCR products displaying a heteroduplex peak were sequenced and compared with the sequence of a homozygous sample.
Sequencing
Prior to sequencing, unincorporated deoxyribonucleotide triphosphates and primers were removed by 0.5 units of shrimp alkaline phosphatase) and 5 units of Exo (exonuclease) I (both from Amersham, Piscataway, NJ, USA) at 37 1C for 30 min, after which the enzymes were inactivated by incubation at 80 1C for 15 min. Samples were sequenced in both directions on an Applied Biosystem's (Foster City, CA, USA) (ABI) 3100 Genetic Analyzer using the Big-dye terminator cycle sequencing reaction kit (Applied Biosystems).
SNP typing MOG V142L was typed by primer extension followed by DHPLC analysis. 53 Deletion of leucine at codon 22 (indel L22) was typed by electrophoresis on the ABI 3100 Genetic Analyzer of the PCR fragment obtained with a Fam-conjugated primer.
The remaining SNPs were typed by the SNaPshot approach (ABI). Two SNaPshot reactions were designed, one for the seven SNPs in the promoter and coding region amplified by a multiplex PCR in three amplicons and one for the four SNPs in the 3 0 -UTR region amplified in one fragment. Samples were electrophoresed on the ABI 3100 Genetic Analyzer. The resulting electropherograms were analysed using the ABI GeneScan 3.7 software.
All primers and conditions are available upon request.
Microsatellite typing
Microsatellite alleles were typed by electrophoresis on the ABI 3100 Genetic Analyzer of PCR fragments obtained with a fluorescence-conjugated primer. Resulting electropherograms were analysed using the ABI GeneScan 3.7 and Genotyper 3.6 NT softwares. PCR primers were as previously reported for TNFa, 54 MIB, 55 MOGCA, 25 D6S1683 56 and D6S2239. 56 Newly designed primers were utilized for D6S265 (forward: 5 0 -ACGTTCGTACCCATTAACCT-3 0 ; reverse: 5 0 -TAACTGG AGGTTCTCATATTA-3 0 ) and MOGTAAA (forward: 5 0 -GTTGCAGTGAGCTGAGATCG-3 0 ; reverse: 5 0 -TGACCT CTGGGGTAATGAGG-3 0 ). Numbering of microsatellite alleles was assigned according to the size of the repeat (the smallest allele ¼ 1). On this basis, the microsatellite allele typing of the International Histocompatibility Workshop reference cell line no. 9031 was TNFa-2, MIB-1, D6S265-6, MOGCA-1, MOGTAAA-10, D6S1683-8, D6S2239-3.
HLA typing MS cases (540) and 558 controls of the case/control set were typed for HLA-DRB1 by the DR low-resolution PCR-SSP (Dynal or BAG, Interlabo diagnostici, Trezzano Rosa, Italy). HLA-DR-typed patients and controls in part overlap with those included in a previous paper. 6 Additional 332 controls and 115 patients of the case/ control set and the members of 232 simplex families (patients and parents) were specifically typed for DRB1*1501. DRB1*1501 typing was performed by allele-specific PCR (with DR15-specific primers: DRB1-15F CCTGTGGCAGCCTAAGAGG and DRB1-15R CCG CGCCTGCTCCAGGAT and an internal control: primers CF TGTTCTGTATTTGTGTTGTCTGATG and CR GTGC TCAGAGAGGCAAGGTT).
Statistical analysis
The association of each polymorphism with the disease was measured by the odds ratio (OR) and its 95% confidence interval (CI). The statistical significance of the difference of gene, genotype and hp frequencies among cases and controls was evaluated by the w 2 test with Yates's correction. When required by the small number of expected cases, the two-tailed Fisher's exact test was used. Reported P-values were not corrected for the number of comparisons.
The Haploview program (version 3.11) 57 was used to estimate hp structures, compare gene and hp frequencies among cases and controls and for TDT analysis.
TDT for microsatellite markers and for their haplotypic combinations was performed by the Genehunter program (version 2.1). 58 AFBAC (affected family-based controls) was performed according to Thomson. 31 Pairwise linkage disequilibria (D' and r 2 ) were evaluated by the Haploview program (version 3.11). 57 Estimates for Global D' and Cramer's V (measures of LD between multiallelic loci) were calculated using the COCAPHASE program, part of the UNPHASED suite. 59 The effect of both MOG L142 and DRB1*15 alleles on MS risk was evaluated by binary logistic regression modelling. OR and 95% CI were computed. The goodness-of-fit between two models was tested by the likelihood ratio test. All analyses were adjusted for sex. Multiplicative interaction between the two alleles was also tested adding an interaction term in the model. Analyses were carried out using SAS v.8.
The main-effects test of the COCAPHASE program 59 was used for conditional analysis on DRB1.
